Study shows Amgen’s new biosimilar cancer drug safe, effective
By Staff Report / Wednesday, September 23rd, 2015 / Latest news, Technology, Top Stories / Comments Off on Study shows Amgen’s new biosimilar cancer drug safe, effective
Pharmaceuticals Amgen and Allergan announced positive Phase 3 study results of their new drug ABP 215 on Sept. 23. The drug, used to treat lung cancer, is being developed as a biosimilar to Roche Holding AG’s Avastin. ABP 215 showed clinical safety and effectiveness compared to Avastin. “Lung cancer is the leading cause of cancer Read More →
Amgen buys biotech company, partners with another
By Staff Report / Wednesday, September 16th, 2015 / Health Care & Life Science, Latest news, Technology, Top Stories, Tri-County Public Companies / Comments Off on Amgen buys biotech company, partners with another
Thousand Oaks-based biopharmaceutical giant Amgen bought a Netherlands-based company and partnered with a Monrovia-based company in an effort to fend off competitors. Amgen announced Sept. 16 that it will buy Dezima, a biotech company focused on developing new treatments for dyslipidemia, a disease where a person has an abnormal amount of lipids in their blood. Read More →
Amgen shares drop as Novartis launches cheaper drug
By Staff Report / Thursday, September 3rd, 2015 / East Ventura County, Health Care & Life Science, Latest news, Top Stories, Tri-County Public Companies / Comments Off on Amgen shares drop as Novartis launches cheaper drug
Amgen, the giant biotech company based in Thousand Oaks, saw its shares drop 2 percent to $149.23 on Sept. 3 after its rival Novartis launched a drug similar to Amgen’s that costs 15 percent less. Novartis’ Zarxio and Amgen’s Neupogen both help chemotherapy patients battle infections by increasing the production of white blood cells. The Read More →
